Dr. Allison Baxley is a pharmacist who is specialized in Oncology in Oklahoma City, Oklahoma. Patients can reach her at 800 Ne 10th St Ste 3029, Oklahoma City or contact her on 405-271-2604. Active license number of Dr. Allison Baxley is 14667 for Oncology in Oklahoma. Dr. Allison Baxley is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Allison Baxley speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Allison Baxley
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
800 Ne 10th St Ste 3029, Oklahoma City, Oklahoma, 73104-5418
Phone:
405-271-2604
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Allison Baxley are as mentioned below.
NPI Number:
1013365089
NPI Enumeration Date:
31 May, 2016
NPI Last Update On:
31 May, 2016
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Allison Baxley are as mentioned below.
Specialization
License Number
State
Status
Oncology
14667
Oklahoma
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1708 Nw 196th St, Edmond, Oklahoma
Zip:
73012-3448
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Allison Baxley at 800 Ne 10th St Ste 3029, Oklahoma City, Oklahoma or can call on phone at 405-271-2604.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.